erenumab sold brand name aimovig medication targets calcitonin generelated peptide receptor cgrpr prevention administered subcutaneous erenumab developed amgen approved may first cgrpr antagonist approved us food drug commonly prescribed medication united states million erenumab indicated prevention migraine common side effects constipation pruritus muscle spasms well mild mostly transient reactions injection erenumab shown interact ethinylestradiol norgestimate migraine drug sumatriptan expected generally low potential interactions metabolized cytochrome erenumab fully human monoclonal antibody blocking calcitonin generelated peptide receptor subcutaneous injection erenumab estimated bioavailability highest blood plasma concentrations reached four six days like proteins substance degraded proteolysis small peptides amino acids elimination halflife erenumab developed amgen inc conjunction phase iii strive clinical trial patients divided three groups ratio group injected subcutaneously monthly mg erenumab period months results measured mean monthly migraine days months baseline patients experienced migraine days per month average medication significantly reduced number migraine days per month group group versus placebo list price reported per united kingdom erenumab approved scottish medicines consortium national institute health care excellence rejected drug basis costeffectiveness sufficiently united states food drug administration approved medication preventive treatment migraine adults may first cgrpr antagonist approved medical use european union july erenumab international nonproprietary name united states adopted httpsenwikipediaorgwikierenumab